SciY is proud to announce a strategic distribution agreement with Allchemy, a pioneer in Artificial Intelligence (AI) driven drug discovery, co-founded by renowned experts Dr. Sara Szymkuć and Prof. Bartosz Grzybowski.
This partnership is set to revolutionize the pharmaceutical landscape by expanding the reach of Allchemy’s innovative drug-discovery platform to new markets and enhancing the research capabilities of scientists worldwide. Image Credit: SciY Related Stories Discover how SciY empowers scientists SciY launches new BioDrive tool and registration module for enhanced data management and collaboration in molecular biology research Under the agreement, SciY will become the exclusive distributor of Allchemy’s cutting-edge computational synthesis and AI algorithms. The Allchemy platform, backed by a profitable business model through licensing and research grants, stands out for its comprehensive suite of tools.
These include advanced retrosynthetic analysis, forward-synthesis exploration, and mechanistic studies, all powered by a unique knowledge base that includes “negative data” to avoid unfeasible pathways. The platform’s scalability extends from lab to industrial levels, considering reaction scale and by-products, ensuring efficiency and sustainability. Allchemy’s AI-driven approach is not just about predicting molecular properties; it’s about innovating the entire synthesis process,” Sara Szymkuć, PhD, Co-Founder and President, Allchemy.
“Our p.